A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Latest Information Update: 23 Aug 2024
At a glance
- Drugs INBRX 109 (Primary)
- Indications Chondrosarcoma
- Focus Registrational; Therapeutic Use
- Acronyms ChonDRAgon
- Sponsors Inhibrx
- 02 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 02 Feb 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Dec 2024.
- 26 Apr 2023 According to an Inhibrx media release, data from the registration-enabling trial in unresectable or metastatic conventional chondrosarcoma is expected during the second half of 2024.